Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Progenitor endothelial cell capturing with drug eluting implantable medical device

A technology for medical equipment and drugs, applied in vascular endothelial cells, biochemical equipment and methods, drug delivery, etc., and can solve problems such as cracking

Active Publication Date: 2014-04-09
ORBUSNEICH MEDICAL PTE LTD
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, coatings of prior art medical devices have shown problems with cracking when the device is implanted

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Progenitor endothelial cell capturing with drug eluting implantable medical device
  • Progenitor endothelial cell capturing with drug eluting implantable medical device
  • Progenitor endothelial cell capturing with drug eluting implantable medical device

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0172] The preparation of embodiment 1 coating composition

[0173] The polymer polyDL-lactide-co-glycolide (DLPLG, Birmingham Polymers) was provided as pellets. To prepare the polymer matrix composition for coating the stents, the pellets were weighed and dissolved in a ketone or dichloromethane solvent to form a solution. The drug was dissolved in the same solvent and added to the polymer solution to the desired concentration, thereby forming a uniform coating solution. The ratio of lactide to glycolide can be varied in order to improve ductility and alter the release kinetics of the coating matrix. This solution is then used to coat scaffolds to form Figure 11 Uniform coating as shown in . Figure 12 A cross-section through a coated stent of the invention is shown. The polymer / drug can be deposited on the surface of the stent using various standard methods.

Embodiment 2

[0174] Example 2 Evaluation of Polymers / Drugs and Concentrations

[0175] Method of spray-coating stents: polymer pellets of DLPLG that have been dissolved in a solvent are mixed with one or more drugs. Alternatively, one or more polymers can be dissolved with a solvent and one or more drugs can be added and mixed. The resulting mixture was evenly applied to the scaffold using standard methods. After coating and drying, the scaffolds were evaluated. The following list illustrates various examples of coating combinations that were investigated using various drugs and including DLPLG and / or combinations thereof. Alternatively, the formulation may consist of a base coat of DLPLG and a top coat of DLPLG or another polymer such as DLPLA and EVAC 25. Abbreviations for drugs and polymers used in coatings are as follows: MPA is mycophenolic acid, RA is retinoic acid; CSA is cyclosporine A; LOV is lovastatin.TM. (mevinolin)); PCT is paclitaxel; PBMA is polybutylmethacrylate, EVAC i...

Embodiment 3

[0200] The following experiments were performed to measure the drug elution profiles of coatings on stents coated by the method described in Example 2. The coating on the stent consisted of 4% paclitaxel and 96% of a 50:50 poly(DL-lactide-co-glycolide) polymer. Each scaffold was coated with 500ug of the coating composition and incubated in 3ml of bovine serum at 37°C for 21 days. Paclitaxel released into serum was measured on each day during the culture period using standard techniques. The experimental results are shown in Figure 13 middle. Such as Figure 13 As shown, the elution profile of paclitaxel release was very slow and controlled as only about 4ug of paclitaxel was released from the stent over the 21 day period.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
pore sizeaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

Description

[0001] Cross References to Related Applications [0002] This application claims the following priority: U.S. Provisional Application 60 / 736,920 (filed November 15, 2005); U.S. Provisional Application 60 / 822,451 (August 15, 2006); 15 August) and U.S. Provisional Application 60 / 822,471 (15 August 2006). The disclosures of all of these applications are hereby incorporated by reference in their entirety. Background of the invention [0003] The present invention relates to medical devices for implantation into vessels or luminal structures within the body. More specifically, the present invention relates to stents and synthetic grafts having coatings, including controlled-release matrices, comprising pharmaceutical compositions with medicinal substances or drugs for direct delivery to surrounding tissue, and for Ligands that capture target cells in vivo. The pharmaceutical composition in the coating can include one or more drugs that have similar or different effects on specif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61L27/28A61L27/54A61L31/08A61L31/16A61F2/91A61F2/915C12N5/074
CPCA61L27/58C12N2510/00A61L27/306A61L29/106C12N5/0692A61F2/915A61L29/16A61F2002/91508A61L29/146A61L2420/08A61L27/34A61L2300/256A61L31/16A61F2230/0021A61F2002/91533A61L27/54A61L2400/12A61F2/0077A61L31/148A61F2/91A61F2002/91525A61F2210/0076A61L31/088A61L31/10A61L27/56A61F2210/0004A61L31/146A61L29/085A61L29/148A61F2230/0013A61F2/00
Inventor R·J·小科顿S·M·劳兰S·帕克M·约克拉维奇M·J·B·库特里克
Owner ORBUSNEICH MEDICAL PTE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com